Survodutide: A Literature Course in Six Modules

Survodutide is an investigational synthetic peptide described in the literature as a dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It appears in preclinical publications under the development code BI 456906 and in clinical reports as survodutide. This page summarises what published studies examined and reported. It does not describe how anyone should use any substance. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health-related decision.

How this course is organised

Module 1: What survodutide is and how it has been studied

Definition and class

Survodutide belongs to the class of multi-receptor incretin-based peptides. Unlike single-target GLP-1 receptor agonists, it was engineered to engage two receptors. The discovery paper described BI 456906 as a novel GCGR/GLP-1R dual agonist with anti-obesity efficacy in preclinical models (PMID 36356832). A later profiling paper described the biomarker work and pharmacological characterisation used to select survodutide as the clinical candidate (PMID 38560764).

Form used in studies

Across the published clinical programme, survodutide was administered subcutaneously on a once-weekly schedule with stepwise dose escalation; the phase 2 obesity trial evaluated weekly subcutaneous maintenance doses of 0.6 mg, 2.4 mg, 3.6 mg and 4.8 mg (PMID 38330987), and the phase 2 liver trial evaluated weekly doses of 2.4 mg, 4.8 mg and 6.0 mg (PMID 38847460). A later report described once-weekly survodutide in adults with obesity in a phase 3 setting (PMID 42253238).

Populations studied

• Adults with overweight or obesity, in dose-finding and later-phase trials (PMID 38330987, PMID 42253238).
• Adults with type 2 diabetes, in a randomised dose-response trial with placebo and an open-label semaglutide comparator (PMID 38095657).
• Adults with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis (PMID 38847460) and adults with obesity and MASLD (PMID 42252333).
• People with cirrhosis, in a study of efficacy, tolerability and pharmacokinetics (PMID 38857788).

Design and baseline papers describe the wider programme: the rationale and design of two randomised phase 3 obesity trials (PMID 39495965), the baseline characteristics of SYNCHRONIZE-1 participants (PMID 41187967), and the rationale and design of a cardiovascular outcomes trial (PMID 39453356).

Limits of the evidence in Module 1

The verified literature describes trials in adults with obesity, type 2 diabetes, MASH/MASLD or cirrhosis. It does not establish characteristics of survodutide in children, in pregnancy, or in people outside those enrolment criteria, and design papers describe planned methods rather than results.

Module 2: Mechanism as described in the literature

The mechanistic rationale in published work rests on combining two receptor pathways in one molecule. GLP-1 receptor agonism is conventionally linked to glucose-dependent insulin secretion and reduced food intake, while glucagon receptor agonism is linked to energy expenditure and hepatic lipid handling. The discovery paper characterised BI 456906 as engaging both receptors and reported robust anti-obesity efficacy in preclinical models (PMID 36356832).

Translational biomarkers

Because dual agonism raises the question of how much glucagon receptor engagement occurs at a given exposure, researchers published a biomarker and pharmacological profiling analysis that supported clinical candidate selection for the GCGR/GLP-1R dual agonist survodutide (PMID 38560764). A narrative review discussed how hepatic and systemic metabolic effects were proposed to intersect in MASH (PMID 39663847).

Limits of the evidence in Module 2

Mechanistic statements derive largely from cell, rodent and biomarker work. The relative contribution of each receptor to any clinical endpoint in humans was not isolated by the trials in this list, and reviews summarise hypotheses rather than test them.

Module 3: Reported outcomes by study

The table below lists what each study examined and what researchers reported. No study in this list demonstrates that any outcome will occur in any individual.

Limits of the evidence in Module 3

Phase 2 trials were dose-finding and were not sized to measure clinical events. Group-level averages do not describe individual trajectories, and cardiovascular outcome data were still being collected under a published trial design rather than reported (PMID 39453356).

Module 4: Survodutide Side Effects: What Studies Report

Adverse events in the published trials were dominated by gastrointestinal complaints, consistent with the incretin-based class. In the phase 2 obesity dose-finding trial, researchers reported that adverse events were mostly gastrointestinal — including nausea, vomiting and diarrhoea — and that they occurred more often with survodutide than with placebo (PMID 38330987). In the phase 2 MASH trial, the study reported that adverse events including nausea, diarrhoea and vomiting were more frequent in the survodutide groups than in the placebo group (PMID 38847460).

The type 2 diabetes dose-response trial also reported tolerability alongside HbA1c and bodyweight outcomes, with gastrointestinal events described across the dose range (PMID 38095657). Tolerability was a named objective of the study in people with cirrhosis (PMID 38857788), and safety reporting also accompanied the phase 3 obesity results (PMID 42253238) and the SYNCHRONIZE-MASLD trial (PMID 42252333).

Two structural points recur in these reports. First, dose escalation schedules were built into the protocols, and tolerability was described in relation to the escalation speed and maintenance dose reached (PMID 38330987). Second, treatment discontinuation because of adverse events was tracked as a tolerability signal in the dose-finding trials (PMID 38847460).

Limits of the evidence in Module 4

Trial safety datasets covered defined populations over trial-length exposure under medical supervision. Rare events, long-term events, interactions with other medicines, and outcomes in people who would have been excluded from these trials were not characterised by the studies listed here.

Module 5: Pharmacokinetics where data exist

Published pharmacokinetic detail for survodutide is narrower than its efficacy literature. The preclinical discovery paper described molecular and pharmacological properties of BI 456906 developed for extended exposure and evaluated in preclinical models (PMID 36356832), and the profiling paper described the pharmacological characterisation that informed clinical candidate selection (PMID 38560764).

In humans, the most specific published pharmacokinetic work in this list came from the hepatology study, which assessed the pharmacokinetics of survodutide alongside efficacy and tolerability in people with cirrhosis (PMID 38857788). Clinically, the once-weekly subcutaneous schedule used in phase 2 and phase 3 trials reflects the exposure profile the programme was built around (PMID 38330987, PMID 42253238).

Limits of the evidence in Module 5

The verified papers do not provide renal-impairment pharmacokinetics, drug–drug interaction studies, bioequivalence comparisons between formulations, or stability and handling data. Absence of a published value is not evidence of a favourable or unfavourable one.

Module 6: Regulatory status, stated factually

Approval status

Survodutide is described throughout the cited literature as an investigational agent under clinical development: phase 2 trials in obesity, type 2 diabetes and MASH were followed by phase 3 trials whose designs were published in advance (PMID 39495965) and by a cardiovascular outcomes trial described in a separate design paper (PMID 39453356). Investigational status means a medicine has not completed regulatory review for marketing in a given jurisdiction; regulatory databases maintained by the FDA and EMA are the authoritative source for current approval status of any product.

Research-use-only material

Peptides distributed with "research use only" (RUO) labelling are, by that label's definition, not approved for human or veterinary administration and are not manufactured to pharmaceutical quality standards. RUO material is not the same product as a drug evaluated in the clinical trials summarised above, and identity, purity and sterility are not verified by any regulator for such material.

Compounding

In the United States, compounding by 503A pharmacies and 503B outsourcing facilities operates under specific statutory conditions, including rules governing which bulk drug substances may be used and restrictions on compounding copies of commercially available approved drugs. Substances that are not components of an FDA-approved drug and are not on the relevant bulk substances lists fall outside those permitted categories. This section states regulatory facts for education and is not legal advice; rules differ by country and change over time.

Limits of the evidence in Module 6

Regulatory status is time-sensitive and jurisdiction-specific. The papers cited here document a clinical development programme; they do not determine what is lawfully available anywhere.

What the studies did not test

• Use outside trial protocols. Every dose in this literature was administered in a supervised trial with defined escalation, monitoring and eligibility criteria (PMID 38847460).
• Long-term outcomes. A cardiovascular outcomes trial was described in a design paper rather than reported as results (PMID 39453356).
• Combination with other peptides or agents. The dose-finding trials compared survodutide with placebo, and one trial included an open-label semaglutide arm (PMID 38095657); no stacking regimens were evaluated.
• Non-clinical-grade material. No study in this list evaluated compounded or research-use-only preparations.
• Durability after stopping. The trials reported on-treatment endpoints over defined periods, such as 46 weeks in the obesity dose-finding trial (PMID 38330987).

This page summarises published research for educational purposes only and is not medical advice; consult a licensed physician about any medical question or medication decision.

References

• BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy (Molecular Metabolism, 2022)
• Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial (Diabetologia, 2024)
• Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (The Lancet Diabetes & Endocrinology, 2024)
• The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection (Diabetes, Obesity & Metabolism, 2024)
• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (The New England Journal of Medicine, 2024)
• Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis (Journal of Hepatology, 2024)
• Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial (JACC: Heart Failure, 2024)
• Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2) (Obesity, 2025)
• Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction (Expert Opinion on Investigational Drugs, 2024)
• Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1) (Diabetes, Obesity & Metabolism, 2026)
• Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (Nature Medicine, 2026)
• Survodutide Once Weekly for the Treatment of Adults with Obesity (The New England Journal of Medicine, 2026)